Results 221 to 230 of about 15,628 (311)

Top 50 most frequent adverse events for Docetaxel at the PT level in patients aged 18–65 from FAERS data.

Lei Wang (6656), Hui Zhao (7395), Kunpeng Yang (7459712), Zhe Wang (41178), Chenglun Cai (21547979), Peiyun Lv (21547976), Bao Wang (488990)   +6 more
openalex   +1 more source

Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference. [PDF]

Ther Adv Drug Saf
Zeng H, Liu W, Li A, Liu H, Li X, Lai J, Chen M, Xiong G, Zhang Y.   +8 more
europepmc   +1 more source

Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy. [PDF]

J Pharm Health Care Sci
Hazama K, Imai T, Tochikura N, Washinosu S, Ootsuka S, Hanada K.   +5 more
europepmc   +1 more source

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database. [PDF]

Jpn J Clin Oncol
Yang Y, Ma W, Fu H, Zhou Y, Lin Y.
europepmc   +1 more source

Characteristics of adolescents with T2D cases reporting ADRs to metformin in FAERS.

Mengsi Peng (12882734), Peng Shen (688111), Kyung-In Joung (15270226), Kwang Joon Kim (7450301)   +3 more
openalex   +1 more source

Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS). [PDF]

Eur J Med Res
Xu L, Huang Z, Chen G, Sun C, Yu Y, Gao S.   +5 more
europepmc   +1 more source